Biocon’s Syngene posts 59% YoY rise in Q1 FY26 profit to ₹87 crore, driven by contract wins and operational efficiency.

• Revenue rose 11% YoY to ₹875 crore; EBITDA up 19% to ₹224 crore with margin at 25%.
• Growth led by pilot-to-contract conversions in research services and expansion in biologics operations in India and the U.S.
• USFDA inspections cleared; over 20 audits affirm quality; Chethan Yogesh named new compliance officer from July 23.